Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s CellCept Gains “Black Box” Warning On Use During Pregnancy

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA reinforces warning on increased risk of miscarriage, congenital deformities in light of postmarketing data from Roche, firm tells “The Pink Sheet” DAILY.

You may also be interested in...



FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs

PML could be a hazard, too, agency says.

FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs

PML could be a hazard, too, agency says.

EMEA Backs Conditional Marketing Of GSK’s Tykerb, Withdrawal Of Novartis’ Prexige In EU

GSK to supply additional data for breast cancer drug; panel okays generics for Roche’s CellCept.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel